Charles River Laboratories International (CRL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
51.4mn → 49.6mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
steady at 5.5% of revenue (−5.9% YoY).
$360.7M returned vs $518.5M of FCF in FY25. Buybacks covered by cash flow.
-4¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Over this window: gross 37.7% → 33.0%. Net margin -3.6% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 3,976.9 | 4,015.4 | 4,050.0 | 4,129.4 | 3,976.1 | 3,540.2 | ▼0.9% | +3.2% |
Cost of revenue | 2,651.3 | 2,692.1 | 2,718.2 | 2,626.9 | 2,513.4 | 2,205.5 | ▼1.0% | +5.1% |
Gross profit | 1,325.6 | 1,323.3 | 1,331.8 | 1,502.6 | 1,462.7 | 1,334.6 | ▼0.6% | −0.2% |
Selling, general & admin | 725.0 | 743.1 | 751.0 | 747.9 | 665.1 | 619.9 | ▼1.1% | +4.6% |
Total operating expenses | 1,166.6 | 1,298.1 | 1,104.5 | 885.3 | 811.7 | 744.8 | ▲17.5% | +14.9% |
Operating incomefeeds ROC rank | 159.0 | 25.2 | 227.3 | 617.3 | 651.0 | 589.9 | ▼88.9% | −54.6% |
Other income, net | −259.2 | −124.7 | −134.2 | −36.0 | −28.0 | −109.2 | — | — |
Pretax income | −100.2 | −99.5 | 93.1 | 581.3 | 623.0 | 480.7 | — | — |
Income tax | −142.8 | 42.7 | 67.8 | 100.9 | 130.4 | 81.9 | ▼37.1% | −15.0% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 40.2 | −144.3 | 22.2 | 474.6 | 486.2 | 398.8 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.96 | −2.91 | 0.20 | 9.22 | 9.48 | 7.60 | — | — |
Diluted shares (mn) | 48.58 | 49.56 | 51.63 | 51.45 | 51.30 | 51.42 | ▼4.0% | −0.9% |
| Margins | ||||||||
Gross margin17th pct in Healthcare | 33.3% | 33.0% | 32.9% | 36.4% | 36.8% | 37.7% | ▲0.1pp | −4.7pp |
Operating margin | 4.0% | 0.6% | 5.6% | 14.9% | 16.4% | 16.7% | ▼5.0pp | −16.0pp |
Net margin43rd pct in Healthcare | 1.0% | −3.6% | 0.5% | 11.5% | 12.2% | 11.3% | ▼4.1pp | −14.9pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Charles River Laboratories International's revenue last fiscal year?
Charles River Laboratories International reported revenue of $4,015.4M in fiscal 2025, down 0.9% from fiscal 2024.
What was Charles River Laboratories International's net income?
Charles River Laboratories International reported net income of −$144.3M in fiscal 2025, a net margin of −3.6%.

